Ireland - English - HPRA (Health Products Regulatory Authority)

biotech pharma limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - bortezomib

Australia - English - Department of Health (Therapeutic Goods Administration)

south eastern sydney local health district - skin, quantity: 1 u - graft - excipient ingredients: glycerol - skin - repair, replacement and regeneration of lost ordamaged skin

United States - English - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - sinecatechins (unii: t432289gyz) (sinecatechins - unii:t432289gyz) - sinecatechins 150 mg in 1 g - veregen® is indicated for the topical treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients 18 years and older. the safety and effectiveness of veregen® have not been established for treatment beyond 16-weeks or for multiple treatment courses. the safety and effectiveness of veregen® in immunosuppressed patients have not been established. none risk summary there are no available data on veregen use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, sinecatechins did not cause malformations, but did affect the developing fetus in the presence of maternal toxicity when given to pregnant rabbits and rats by intravaginal or systemic routes of administration during the period of organogenesis (see data ). the available data do not allow the calculation of relevant comparisons between the systemic exposure of sinecatechins observed in the animal studie

Australia - English - Department of Health (Therapeutic Goods Administration)

victorian institute of forensic medicine t/a donor tissue bank of victoria - skin, quantity: 24 cm2 - graft - excipient ingredients: - skin - treatment of dermatological disorder/disease/trauma

Australia - English - Department of Health (Therapeutic Goods Administration)

metro south hospital and health service t/a queensland tissue bank - skin, quantity: 1 u - graft - excipient ingredients: glycerol; glucose monohydrate; ascorbic acid; polysorbate 80; sodium chloride; dibasic sodium phosphate; guanine hydrochloride monohydrate; monobasic potassium phosphate; dried magnesium sulfate; aminobenzoic acid; adenine sulfate dihydrate; alanine; arginine hydrochloride; aspartic acid; biotin; cholesterol; calcium chloride dihydrate; cysteine hydrochloride monohydrate; cystine; choline chloride; calcium pantothenate; deoxyribose; ergocalciferol; ferric nitrate nonahydrate; folic acid; glycine; glutamic acid; glutathione; histidine hydrochloride monohydrate; hydroxyproline; sodium hypoxanthine; isoleucine; inositol; leucine; betaine; methionine; menadione; nicotinic acid; nicotinamide; phenolsulfonphthalein; potassium chloride; pyridoxal hydrochloride; pyridoxine hydrochloride; phenylalanine; proline; retinol acetate; riboflavin; ribose; serine; sodium acetate; sodium bicarbonate; thymine; tyrosine disodium; thiamine hydrochloride; dl-alpha-tocopheryl phosphate disodium; threonine; tryptophan; uracil; valine; sodium xanthine; adenosine phosphate; adenosine triphosphate disodium trihydrate - skin - restoration/repair of dermatological function

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - imatinib mesilate - film-coated tablet - 100 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib actavis group is indicated for the treatment of - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult patients with ph+ cml in blast crisis. - adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr
rearrangement.

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - imatinib mesylate - film-coated tablet - 400 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib actavis group is indicated for the treatment of - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult patients with ph+ cml in blast crisis. - adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr
rearrangement.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

timothy grass) 10hep solution for skin prick test 2ml vials (alk-abello ltd - timothy grass (phleum pratense) pollen allergen extract - solution for skin-prick test

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

biotech laboratories (pty) ltd - capsules - see ingredients - each capsule contains indomethacin 25 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

carolines skincare - 47156 - skin detergent - a low irritant, mild skin care conditioning, wash formulation designed to gently cleanse dry, as well as acne and eczema prone skin. helps the skin retain moisture and supports a healthy skin / epidermal barrier function. helps to soothe / moderate / ease itch and irritation. helps to reduce trans-epidermal moisture loss, with emollient oils and skin conditioners, humectant, and mucilage agents to protect and soothe the skin and help reduce the stripping and irritation that other forming cleanser can cause. helps to supplement epidermal fatty acids for improved natural moisturising, supporting normal healthy skin function.